Early clinical experience with an integrated continuous glucose sensor/insulin pump platform

Achieving tight glycemic control to the HbAlc targets established by the ADA and other Diabetes Organizations is predicated upon the patient's ability to perform sufficient and timely self monitoring of blood glucose and to delivery the appropriate therapy in response to these glucose values. The intermittent nature of fingerstick monitoring is not ideally suited to meet this challenge. In this paper, we report the results from a feasibility study in which a new product platform combining real-time continuous glucose monitoring with insulin pump therapy is evaluated.